This is the authors' abstract. We don't add key points for this paper.
Chemoenzymatic peptide synthesis offers a sustainable alternative to traditional solid-phase peptide synthesis for manufacturing therapeutic peptides such as semaglutide. However, cost-efficient industrial implementation requires enzyme immobilization to enable the catalyst recovery and continuous processing. This work presents the first demonstration of a bioinformatics-guided immobilization strategy for a peptiligase variant, successfully applied in a continuous-flow packed-bed reactor for semaglutide fragment ligation. Using computational tools, we predicted optimal immobilization sites and systematically screened covalent and noncovalent methods. EP400/SS-aldehyde emerged as the superior support, maintaining >85% of the immobilized activity after 10 reuse cycles. Translation to continuous flow revealed substrate hydrolysis as a competing side reaction at high enzyme loads. Optimization of the protein loading, to 2.5 mg/g, suppressed this unwanted reaction, achieving 95% conversion with 30 min of residence time, matching solution-phase performance. This establishes a robust framework for immobilizing peptiligases in industrial bioprocesses.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Regueiro et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: